1. Hosseinidoust, Z.; Mostaghaci, B.; Yasa, O.; Park, B. W.; Singh, A. V.; Sitti, M. Bioengineered and biohybrid bacteria-based systems for drug delivery. Adv Drug Deliv Rev. 2016, 106, 27-44.  2. Zhou, S.; Gravekamp, C.; Bermudes, D.; Liu, K. Tumour-targeting bacteria engineered to fight cancer. Nat Rev Cancer. 2018, 18, 727-743.  3. Dolgin, E. Fighting cancer with microbes. Nature. 2020, 577, S16-S18.  4. McAdams, H. H.; Srinivasan, B.; Arkin, A. P. The evolution of genetic regulatory systems in bacteria. Nat Rev Genet. 2004, 5, 169-178.  5. Zu, C.; Wang, J. Tumor-colonizing bacteria: a potential tumor targeting therapy. Crit Rev Microbiol. 2014, 40, 225-235.  6. Suh, S.; Jo, A.; Traore, M. A.; Zhan, Y.; Coutermarsh-Ott, S. L.; Ringel-Scaia, V. M.; Allen, I. C.; Davis, R. M.; Behkam, B. Nanoscale bacteria-enabled autonomous drug delivery system (NanoBEADS) enhances intratumoral transport of nanomedicine. Adv Sci (Weinh). 2019, 6, 1801309.  7. Zitvogel, L.; Daillère, R.; Roberti, M. P.; Routy, B.; Kroemer, G. Anticancer effects of the microbiome and its products. Nat Rev Microbiol. 2017, 15, 465-478.  8. Li, J.; Sung, C. Y.; Lee, N.; Ni, Y.; Pihlajamäki, J.; Panagiotou, G.; El-Nezami, H. Probiotics modulated gut microbiota suppresses hepatocellular carcinoma growth in mice. Proc Natl Acad Sci U S A. 2016, 113, E1306-1315.  9. Roy, S.; Trinchieri, G. Microbiota: a key orchestrator of cancer therapy. Nat Rev Cancer. 2017, 17, 271-285.  10. Chen, Q. W.; Qiao, J. Y.; Liu, X. H.; Zhang, C.; Zhang, X. Z. Customized materials-assisted microorganisms in tumor therapeutics. Chem Soc Rev. 2021, 50, 12576-12615.  11. Chen, W.; Wang, J.; Du, L.; Chen, J.; Zheng, Q.; Li, P.; Du, B.; Fang, X.; Liao, Z. Kefir microbiota and metabolites stimulate intestinal mucosal immunity and its early development. Crit Rev Food Sci Nutr. 2022, doi: 10.1080/10408398.2022.2115975.  12. Paiva, A. D.; de Oliveira, M. D.; de Paula, S. O.; Baracat-Pereira, M. C.; Breukink, E.; Mantovani, H. C. Toxicity of bovicin HC5 against mammalian cell lines and the role of cholesterol in bacteriocin activity. Microbiology (Reading). 2012, 158, 2851-2858.  13. Cao, J.; Zaremba, O. T.; Lei, Q.; Ploetz, E.; Wuttke, S.; Zhu, W. Artificial bioaugmentation of biomacromolecules and living organisms for biomedical applications. ACS Nano. 2021, 15, 3900-3926.  14. Guo, Z.; Richardson, J. J.; Kong, B.; Liang, K. Nanobiohybrids: materials approaches for bioaugmentation. Sci Adv. 2020, 6, eaaz0330.  15. Yao, S.; Jin, B.; Liu, Z.; Shao, C.; Zhao, R.; Wang, X.; Tang, R. Biomineralization: from material tactics to biological strategy. Adv Mater. 2017, 29, 1605903.  16. Magennis, E. P.; Fernandez-Trillo, F.; Sui, C.; Spain, S. G.; Bradshaw, D. J.; Churchley, D.; Mantovani, G.; Winzer, K.; Alexander, C. Bacteria-instructed synthesis of polymers for self-selective microbial binding and labelling. Nat Mater. 2014, 13, 748-755.  17. Li, Y.; Beitelshees, M.; Fang, L.; Hill, A.; Ahmadi, M. K.; Chen, M.; Davidson, B. A.; Knight, P., 3rd; Smith, R. J., Jr.; Andreadis, S. T.; Hakansson, A. P.; Jones, C. H.; Pfeifer, B. A. In situ pneumococcal vaccine production and delivery through a hybrid biological-biomaterial vector. Sci Adv. 2016, 2, e1600264.  18. Huang, Y.; Zeng, H.; Xie, L.; Gao, R.; Zhou, S.; Liang, Q.; Zhang, X.; Liang, K.; Jiang, L.; Kong, B. Super-assembled chiral mesostructured heteromembranes for smart and sensitive couple-accelerated enantioseparation. J Am Chem Soc. 2022, 144, 13794-13805.  19. Yan, M.; Liu, T.; Li, X.; Zhou, S.; Zeng, H.; Liang, Q.; Liang, K.; Wei, X.; Wang, J.; Gu, Z.; Jiang, L.; Zhao, D.; Kong, B. Soft patch interface-oriented superassembly of complex hollow nanoarchitectures for smart dual-responsive nanospacecrafts. J Am Chem Soc. 2022, 144, 7778-7789.  20. Yan, M.; Xie, L.; Tang, J.; Liang, K.; Mei, Y.; Kong, B. Recent advances in heterosilica-based micro/nanomotors: designs, biomedical applications, and future perspectives. Chem Mater. 2021, 33, 3022-3046.  21. Mostaghaci, B.; Yasa, O.; Zhuang, J.; Sitti, M. Bioadhesive bacterial microswimmers for targeted drug delivery in the urinary and gastrointestinal tracts. Adv Sci (Weinh). 2017, 4, 1700058.  22. Alapan, Y.; Yasa, O.; Schauer, O.; Giltinan, J.; Tabak, A. F.; Sourjik, V.; Sitti, M. Soft erythrocyte-based bacterial microswimmers for cargo delivery. Sci Robot. 2018, 3, eaar4423.  23. Vargason, A. M.; Santhosh, S.; Anselmo, A. C. Surface modifications for improved delivery and function of therapeutic bacteria. Small. 2020, 16, e2001705.  24. Fan, J. X.; Li, Z. H.; Liu, X. H.; Zheng, D. W.; Chen, Y.; Zhang, X. Z. Bacteria-mediated tumor therapy utilizing photothermally-controlled TNF-α expression via oral administration. Nano Lett. 2018, 18, 2373-2380.  25. Zheng, J. H.; Nguyen, V. H.; Jiang, S. N.; Park, S. H.; Tan, W.; Hong, S. H.; Shin, M. G.; Chung, I. J.; Hong, Y.; Bom, H. S.; Choy, H. E.; Lee, S. E.; Rhee, J. H.; Min, J. J. Two-step enhanced cancer immunotherapy with engineered Salmonella typhimurium secreting heterologous flagellin. Sci Transl Med. 2017, 9, eaak9537.  26. Johnston, T. G.; Yuan, S. F.; Wagner, J. M.; Yi, X.; Saha, A.; Smith, P.; Nelson, A.; Alper, H. S. Compartmentalized microbes and co-cultures in hydrogels for on-demand bioproduction and preservation. Nat Commun. 2020, 11, 563.  27. Dai, Z.; Lee, A. J.; Roberts, S.; Sysoeva, T. A.; Huang, S.; Dzuricky, M.; Yang, X.; Zhang, X.; Liu, Z.; Chilkoti, A.; You, L. Versatile biomanufacturing through stimulus-responsive cell-material feedback. Nat Chem Biol. 2019, 15, 1017-1024.  28. Anselmo, A. C.; McHugh, K. J.; Webster, J.; Langer, R.; Jaklenec, A. Layer-by-layer encapsulation of probiotics for delivery to the microbiome. Adv Mater. 2016, 28, 9486-9490.  29. Lou, X.; Chen, Z.; He, Z.; Sun, M.; Sun, J. Bacteria-mediated synergistic cancer therapy: small microbiome has a big hope. Nanomicro Lett. 2021, 13, 37.  30. Cao, Z.; Liu, J. Bacteria and bacterial derivatives as drug carriers for cancer therapy. J Control Release. 2020, 326, 396-407.  31. Chen, Q. W.; Wang, J. W.; Wang, X. N.; Fan, J. X.; Liu, X. H.; Li, B.; Han, Z. Y.; Cheng, S. X.; Zhang, X. Z. Inhibition of tumor progression through the coupling of bacterial respiration with tumor metabolism. Angew Chem Int Ed Engl. 2020, 59, 21562-21570.  32. Huang, X.; Pan, J.; Xu, F.; Shao, B.; Wang, Y.; Guo, X.; Zhou, S. Bacteria-based cancer immunotherapy. Adv Sci (Weinh). 2021, 8, 2003572.  33. Helmink, B. A.; Khan, M. A. W.; Hermann, A.; Gopalakrishnan, V.; Wargo, J. A. The microbiome, cancer, and cancer therapy. Nat Med. 2019, 25, 377-388.  34. Schwabe, R. F.; Jobin, C. The microbiome and cancer. Nat Rev Cancer. 2013, 13, 800-812.  35. Arthur, J. C.; Perez-Chanona, E.; Mühlbauer, M.; Tomkovich, S.; Uronis, J. M.; Fan, T. J.; Campbell, B. J.; Abujamel, T.; Dogan, B.; Rogers, A. B.; Rhodes, J. M.; Stintzi, A.; Simpson, K. W.; Hansen, J. J.; Keku, T. O.; Fodor, A. A.; Jobin, C. Intestinal inflammation targets cancer-inducing activity of the microbiota. Science. 2012, 338, 120-123.  36. Yu, T.; Guo, F.; Yu, Y.; Sun, T.; Ma, D.; Han, J.; Qian, Y.; Kryczek, I.; Sun, D.; Nagarsheth, N.; Chen, Y.; Chen, H.; Hong, J.; Zou, W.; Fang, J. Y. Fusobacterium nucleatum promotes chemoresistance to colorectal cancer by modulating autophagy. Cell. 2017, 170, 548-563.e16.  37. Zagato, E.; Pozzi, C.; Bertocchi, A.; Schioppa, T.; Saccheri, F.; Guglietta, S.; Fosso, B.; Melocchi, L.; Nizzoli, G.; Troisi, J.; Marzano, M.; Oresta, B.; Spadoni, I.; Atarashi, K.; Carloni, S.; Arioli, S.; Fornasa, G.; Asnicar, F.; Segata, N.; Guglielmetti, S.; Honda, K.; Pesole, G.; Vermi, W.; Penna, G.; Rescigno, M. Endogenous murine microbiota member Faecalibaculum rodentium and its human homologue protect from intestinal tumour growth. Nat Microbiol. 2020, 5, 511-524.  38. Atasheva, S.; Emerson, C. C.; Yao, J.; Young, C.; Stewart, P. L.; Shayakhmetov, D. M. Systemic cancer therapy with engineered adenovirus that evades innate immunity. Sci Transl Med. 2020, 12, eabc6659.  39. Lui, L. T.; Xue, X.; Sui, C.; Brown, A.; Pritchard, D. I.; Halliday, N.; Winzer, K.; Howdle, S. M.; Fernandez-Trillo, F.; Krasnogor, N.; Alexander, C. Bacteria clustering by polymers induces the expression of quorum-sensing-controlled phenotypes. Nat Chem. 2013, 5, 1058-1065.  40. Wei, B.; Pan, J.; Yuan, R.; Shao, B.; Wang, Y.; Guo, X.; Zhou, S. Polarization of tumor-associated macrophages by nanoparticle-loaded Escherichia coli combined with immunogenic cell death for cancer immunotherapy. Nano Lett. 2021, 21, 4231-4240.  41. Cao, Z.; Wang, X.; Pang, Y.; Cheng, S.; Liu, J. Biointerfacial self-assembly generates lipid membrane coated bacteria for enhanced oral delivery and treatment. Nat Commun. 2019, 10, 5783.  42. Drachuk, I.; Calabrese, R.; Harbaugh, S.; Kelley-Loughnane, N.; Kaplan, D. L.; Stone, M.; Tsukruk, V. V. Silk macromolecules with amino acid-poly(ethylene glycol) grafts for controlling layer-by-layer encapsulation and aggregation of recombinant bacterial cells. ACS Nano. 2015, 9, 1219-1235.  43. Zhou, X.; Zeng, Y.; Tang, Y.; Huang, Y.; Lv, F.; Liu, L.; Wang, S. Artificial regulation of state transition for augmenting plant photosynthesis using synthetic light-harvesting polymer materials. Sci Adv. 2020, 6, eabc5237.  44. Gai, P.; Yu, W.; Zhao, H.; Qi, R.; Li, F.; Liu, L.; Lv, F.; Wang, S. Solar-powered organic semiconductor-bacteria biohybrids for CO2 reduction into acetic acid. Angew Chem Int Ed Engl. 2020, 59, 7224-7229.  45. Cao, Z.; Cheng, S.; Wang, X.; Pang, Y.; Liu, J. Camouflaging bacteria by wrapping with cell membranes. Nat Commun. 2019, 10, 3452.  46. Lv, P.; Liu, X.; Chen, X.; Liu, C.; Zhang, Y.; Chu, C.; Wang, J.; Wang, X.; Chen, X.; Liu, G. Genetically engineered cell membrane nanovesicles for oncolytic adenovirus delivery: a versatile platform for cancer virotherapy. Nano Lett. 2019, 19, 2993-3001.  47. Chodisetti, P. K.; Reddy, M. Peptidoglycan hydrolase of an unusual cross-link cleavage specificity contributes to bacterial cell wall synthesis. Proc Natl Acad Sci U S A. 2019, 116, 7825-7830.  48. Luo, G. F.; Chen, W. H.; Zeng, X.; Zhang, X. Z. Cell primitive-based biomimetic functional materials for enhanced cancer therapy. Chem Soc Rev. 2021, 50, 945-985.  49. Spicer, C. D.; Pashuck, E. T.; Stevens, M. M. Achieving controlled biomolecule-biomaterial conjugation. Chem Rev. 2018, 118, 7702-7743.  50. Ojkic, N.; Serbanescu, D.; Banerjee, S. Surface-to-volume scaling and aspect ratio preservation in rod-shaped bacteria. eLife. 2019, 8, e47033.  51. Taherkhani, S.; Mohammadi, M.; Daoud, J.; Martel, S.; Tabrizian, M. Covalent binding of nanoliposomes to the surface of magnetotactic bacteria for the synthesis of self-propelled therapeutic agents. ACS Nano. 2014, 8, 5049-5060.  52. Felfoul, O.; Mohammadi, M.; Taherkhani, S.; de Lanauze, D.; Zhong Xu, Y.; Loghin, D.; Essa, S.; Jancik, S.; Houle, D.; Lafleur, M.; Gaboury, L.; Tabrizian, M.; Kaou, N.; Atkin, M.; Vuong, T.; Batist, G.; Beauchemin, N.; Radzioch, D.; Martel, S. Magneto-aerotactic bacteria deliver drug-containing nanoliposomes to tumour hypoxic regions. Nat Nanotechnol. 2016, 11, 941-947.  53. Fan, J. X.; Peng, M. Y.; Wang, H.; Zheng, H. R.; Liu, Z. L.; Li, C. X.; Wang, X. N.; Liu, X. H.; Cheng, S. X.; Zhang, X. Z. Engineered bacterial bioreactor for tumor therapy via fenton-like reaction with localized H2O2 generation. Adv Mater. 2019, 31, e1808278.  54. Kim, H.; Shin, K.; Park, O. K.; Choi, D.; Kim, H. D.; Baik, S.; Lee, S. H.; Kwon, S. H.; Yarema, K. J.; Hong, J.; Hyeon, T.; Hwang, N. S. General and facile coating of single cells via mild reduction. J Am Chem Soc. 2018, 140, 1199-1202.  55. Chen, F.; Li, X.; Hihath, J.; Huang, Z.; Tao, N. Effect of anchoring groups on single-molecule conductance: comparative study of thiol-, amine-, and carboxylic-acid-terminated molecules. J Am Chem Soc. 2006, 128, 15874-15881.  56. Yin, H.; Kauffman, K. J.; Anderson, D. G. Delivery technologies for genome editing. Nat Rev Drug Discov. 2017, 16, 387-399.  57. Riglar, D. T.; Giessen, T. W.; Baym, M.; Kerns, S. J.; Niederhuber, M. J.; Bronson, R. T.; Kotula, J. W.; Gerber, G. K.; Way, J. C.; Silver, P. A. Engineered bacteria can function in the mammalian gut long-term as live diagnostics of inflammation. Nat Biotechnol. 2017, 35, 653-658.  58. Gurbatri, C. R.; Lia, I.; Vincent, R.; Coker, C.; Castro, S.; Treuting, P. M.; Hinchliffe, T. E.; Arpaia, N.; Danino, T. Engineered probiotics for local tumor delivery of checkpoint blockade nanobodies. Sci Transl Med. 2020, 12, eaax0876.  59. Deng, X.; Yang, W.; Shao, Z.; Zhao, Y. Genetically modified bacteria for targeted phototherapy of tumor. Biomaterials. 2021, 272, 120809.  60. Vargason, A. M.; Anselmo, A. C. Clinical translation of microbe-based therapies: Current clinical landscape and preclinical outlook. Bioeng Transl Med. 2018, 3, 124-137.  61. Singh, A. V.; Hosseinidoust, Z.; Park, B. W.; Yasa, O.; Sitti, M. Microemulsion-based soft bacteria-driven microswimmers for active cargo delivery. ACS Nano. 2017, 11, 9759-9769.  62. Hu, Q.; Sun, W.; Qian, C.; Wang, C.; Bomba, H. N.; Gu, Z. Anticancer platelet-mimicking nanovehicles. Adv Mater. 2015, 27, 7043-7050.  63. Liu, W. L.; Zou, M. Z.; Liu, T.; Zeng, J. Y.; Li, X.; Yu, W. Y.; Li, C. X.; Ye, J. J.; Song, W.; Feng, J.; Zhang, X. Z. Expandable immunotherapeutic nanoplatforms engineered from cytomembranes of hybrid cells derived from cancer and dendritic cells. Adv Mater. 2019, 31, e1900499.  64. Abdi-Ali, A.; Worobec, E. A.; Deezagi, A.; Malekzadeh, F. Cytotoxic effects of pyocin S2 produced by Pseudomonas aeruginosa on the growth of three human cell lines. Can J Microbiol. 2004, 50, 375-381.  65. Mercado-Lubo, R.; Zhang, Y.; Zhao, L.; Rossi, K.; Wu, X.; Zou, Y.; Castillo, A.; Leonard, J.; Bortell, R.; Greiner, D. L.; Shultz, L. D.; Han, G.; McCormick, B. A. A Salmonella nanoparticle mimic overcomes multidrug resistance in tumours. Nat Commun. 2016, 7, 12225.  66. Felgner, S.; Kocijancic, D.; Frahm, M.; Heise, U.; Rohde, M.; Zimmermann, K.; Falk, C.; Erhardt, M.; Weiss, S. Engineered Salmonella enterica serovar Typhimurium overcomes limitations of anti-bacterial immunity in bacteria-mediated tumor therapy. Oncoimmunology. 2018, 7, e1382791.  67. Fritz, S. E.; Henson, M. S.; Greengard, E.; Winter, A. L.; Stuebner, K. M.; Yoon, U.; Wilk, V. L.; Borgatti, A.; Augustin, L. B.; Modiano, J. F.; Saltzman, D. A. A phase I clinical study to evaluate safety of orally administered, genetically engineered Salmonella enterica serovar Typhimurium for canine osteosarcoma. Vet Med Sci. 2016, 2, 179-190.  68. Chowdhury, S.; Castro, S.; Coker, C.; Hinchliffe, T. E.; Arpaia, N.; Danino, T. Programmable bacteria induce durable tumor regression and systemic antitumor immunity. Nat Med. 2019, 25, 1057-1063.  69. Kucerova, P.; Cervinkova, M. Spontaneous regression of tumour and the role of microbial infection--possibilities for cancer treatment. Anticancer Drugs. 2016, 27, 269-277.  70. Viaud, S.; Saccheri, F.; Mignot, G.; Yamazaki, T.; Daillère, R.; Hannani, D.; Enot, D. P.; Pfirschke, C.; Engblom, C.; Pittet, M. J.; Schlitzer, A.; Ginhoux, F.; Apetoh, L.; Chachaty, E.; Woerther, P. L.; Eberl, G.; Bérard, M.; Ecobichon, C.; Clermont, D.; Bizet, C.; Gaboriau-Routhiau, V.; Cerf-Bensussan, N.; Opolon, P.; Yessaad, N.; Vivier, E.; Ryffel, B.; Elson, C. O.; Doré, J.; Kroemer, G.; Lepage, P.; Boneca, I. G.; Ghiringhelli, F.; Zitvogel, L. The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide. Science. 2013, 342, 971-976.  71. Chumchalová, J.; Smarda, J. Human tumor cells are selectively inhibited by colicins. Folia Microbiol (Praha). 2003, 48, 111-115.  72. Baindara, P.; Gautam, A.; Raghava, G. P. S.; Korpole, S. Anticancer properties of a defensin like class IId bacteriocin Laterosporulin10. Sci Rep. 2017, 7, 46541.  73. Begde, D.; Bundale, S.; Mashitha, P.; Rudra, J.; Nashikkar, N.; Upadhyay, A. Immunomodulatory efficacy of nisin--a bacterial lantibiotic peptide. J Pept Sci. 2011, 17, 438-444.  74. Kamarajan, P.; Hayami, T.; Matte, B.; Liu, Y.; Danciu, T.; Ramamoorthy, A.; Worden, F.; Kapila, S.; Kapila, Y. Nisin ZP, a bacteriocin and food preservative, inhibits head and neck cancer tumorigenesis and prolongs survival. PLoS One. 2015, 10, e0131008.  75. Lim, Y. C.; Kim, C. H.; Kim, Y. B.; Joo, J. Y.; Shin, Y. S.; Chung, J. Incidence and risk factors for rebleeding during cerebral angiography for ruptured intracranial aneurysms. Yonsei Med J. 2015, 56, 403-409.  76. Ritz, B. W. Supplementation with active hexose correlated compound increases survival following infectious challenge in mice. Nutr Rev. 2008, 66, 526-531.  77. Geller, A.; Shrestha, R.; Yan, J. Yeast-derived β-glucan in cancer: novel uses of a traditional therapeutic. Int J Mol Sci. 2019, 20, 3618.  78. Kidd, P. M. The use of mushroom glucans and proteoglycans in cancer treatment. Altern Med Rev. 2000, 5, 4-27.  79. Wong, J. H.; Sze, S. C. W.; Ng, T. B.; Cheung, R. C. F.; Tam, C.; Zhang, K. Y.; Dan, X.; Chan, Y. S.; Cho, W. C.; Ng, C. C. W.; Waye, M. M. Y.; Liang, W.; Zhang, J.; Yang, J.; Ye, X.; Lin, J.; Ye, X.; Wang, H.; Liu, F.; Chan, D. W.; Ngan, H. Y. S.; Sha, O.; Li, G.; Tse, R.; Tse, T. F.; Chan, H. Apoptosis and anti-cancer drug discovery: the power of medicinal fungi and plants. Curr Med Chem. 2018, 25, 5613-5630.  80. Martínez Andrade, K. A.; Lauritano, C.; Romano, G.; Ianora, A. Marine microalgae with anti-cancer properties. Mar Drugs. 2018, 16, 165.  81. Cha, K. H.; Koo, S. Y.; Lee, D. U. Antiproliferative effects of carotenoids extracted from Chlorella ellipsoidea and Chlorella vulgaris on human colon cancer cells. J Agric Food Chem. 2008, 56, 10521-10526.  82. Shishlyannikov, S. M.; Klimenkov, I. V.; Bedoshvili, Y. D.; Mikhailov, I. S.; Gorshkov, A. G. Effect of mixotrophic growth on the ultrastructure and fatty acid composition of the diatom Synedra acus from Lake Baikal. J Biol Res (Thessalon). 2014, 21, 15.  83. Nappo, M.; Berkov, S.; Massucco, C.; Di Maria, V.; Bastida, J.; Codina, C.; Avila, C.; Messina, P.; Zupo, V.; Zupo, S. Apoptotic activity of the marine diatom Cocconeis scutellum and eicosapentaenoic acid in BT20 cells. Pharm Biol. 2012, 50, 529-535.  84. Duong, M. T.; Qin, Y.; You, S. H.; Min, J. J. Bacteria-cancer interactions: bacteria-based cancer therapy. Exp Mol Med. 2019, 51, 1-15.  85. Raja, J.; Ludwig, J. M.; Gettinger, S. N.; Schalper, K. A.; Kim, H. S. Oncolytic virus immunotherapy: future prospects for oncology. J Immunother Cancer. 2018, 6, 140.  86. Liu, X.; Yin, S.; Chen, Y.; Wu, Y.; Zheng, W.; Dong, H.; Bai, Y.; Qin, Y.; Li, J.; Feng, S.; Zhao, P. LPS-induced proinflammatory cytokine expression in human airway epithelial cells and macrophages via NF‑κB, STAT3 or AP‑1 activation. Mol Med Rep. 2018, 17, 5484-5491.  87. Aykut, B.; Pushalkar, S.; Chen, R.; Li, Q.; Abengozar, R.; Kim, J. I.; Shadaloey, S. A.; Wu, D.; Preiss, P.; Verma, N.; Guo, Y.; Saxena, A.; Vardhan, M.; Diskin, B.; Wang, W.; Leinwand, J.; Kurz, E.; Kochen Rossi, J. A.; Hundeyin, M.; Zambrinis, C.; Li, X.; Saxena, D.; Miller, G. The fungal mycobiome promotes pancreatic oncogenesis via activation of MBL. Nature. 2019, 574, 264-267.  88. Sepich-Poore, G. D.; Zitvogel, L.; Straussman, R.; Hasty, J.; Wargo, J. A.; Knight, R. The microbiome and human cancer. Science. 2021, 371, eabc4552.  89. Chen, Y.; Zhang, F.; Wang, Q.; Tong, R.; Lin, H.; Qu, F. Near-infrared light-mediated LA-UCNPs@SiO(2)-C/HA@mSiO(2)-DOX@NB nanocomposite for chemotherapy/PDT/PTT and imaging. Dalton Trans. 2017, 46, 14293-14300.  90. Gulzar, A.; Xu, J.; Yang, D.; Xu, L.; He, F.; Gai, S.; Yang, P. Nano-graphene oxide-UCNP-Ce6 covalently constructed nanocomposites for NIR-mediated bioimaging and PTT/PDT combinatorial therapy. Dalton Trans. 2018, 47, 3931-3939.  91. Doppalapudi, R.; Vundavalli, S.; Prabhat, M. P. Effect of probiotic bacteria on oral Candida in head- and neck-radiotherapy patients: A randomized clinical trial. J Cancer Res Ther. 2020, 16, 470-477.  92. Liu, J.; Liu, C.; Yue, J. Radiotherapy and the gut microbiome: facts and fiction. Radiat Oncol. 2021, 16, 9.  93. Mondal, M.; Guo, J.; He, P.; Zhou, D. Recent advances of oncolytic virus in cancer therapy. Hum Vaccin Immunother. 2020, 16, 2389-2402.  94. Harrington, K.; Freeman, D. J.; Kelly, B.; Harper, J.; Soria, J. C. Optimizing oncolytic virotherapy in cancer treatment. Nat Rev Drug Discov. 2019, 18, 689-706.  95. Watanabe, D.; Goshima, F. Oncolytic virotherapy by HSV. Adv Exp Med Biol. 2018, 1045, 63-84.  96. Kanai, R.; Wakimoto, H.; Cheema, T.; Rabkin, S. D. Oncolytic herpes simplex virus vectors and chemotherapy: are combinatorial strategies more effective for cancer? Future Oncol. 2010, 6, 619-634.  97. Kwan, A.; Winder, N.; Muthana, M. Oncolytic virotherapy treatment of breast cancer: barriers and recent advances. Viruses. 2021, 13, 1128.  98. Wang, G.; Kang, X.; Chen, K. S.; Jehng, T.; Jones, L.; Chen, J.; Huang, X. F.; Chen, S. Y. An engineered oncolytic virus expressing PD-L1 inhibitors activates tumor neoantigen-specific T cell responses. Nat Commun. 2020, 11, 1395.